Titre : | Blood naltrexone and 6-ß-naltrexol levels following naltrexone implant: comparing two naltrexone implants |
Titre traduit : | (Les concentrations sanguines en naltrexone et 6-beta-naltrexol suite à la mise en place d'un implant de naltrexone : comparaison de deux implants de naltrexone.) |
Auteurs : | G. K. HULSE ; D. E. ARNOLD-REED ; G. O'NEIL ; C. T. CHAN ; R. HANSSON ; P. O'NEIL |
Type de document : | Périodique |
Année de publication : | 2004 |
Format : | p.59-65 / graph. |
Note générale : |
Addiction Biology, 2004, 9, (1), 59-65, graph.
|
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés NALTREXONE ; VOIE SOUSCUTANEE ; POSOLOGIE ; DOSE-REPONSE ; COMPARAISON ; EFFICACITE |
Résumé : | The aim of this study was to profile and compare blood naltrexone and 6-ß-naltrexol levels with time following treatment with two sustained-release naltrexone preparations produced by GoMedical lndustries, Australia at a community heroin treatment clinic in Penh, Western Australia. A sample of 10 patients who each received a 1.7 g naltrexone implant were compared to 24 patients who each received a 3.4 g naltrexone implant as treatment for heroin dependence. Blood naltrexone levels following treatment with the 1.7 g naltrexone implant remained above 2 and 1 ng/ml for approximately 90 and 136 days, respectively. Use of the 3.4 g naltrexone implant extended the period of coverage to approximately 297 (1 ng/ml) or 188 (2 ng/ml) days. Blood 6-ß- naltrexol levels remained above 10 ng/ml for approximately 18 and 83 days, respectively, following use of the 1.7 g and 3.4 g naltrexone implants. The current study data indicate that blood naltrexone and 6-ß-naltrexol levels following treatment with either the 1.7 g or 3.4 g naltrexone implant are greater than those reported in other published data on other sustained-release naltrexone preparations. Furthermore, duration of blood naltrexone and 6-ß-naltrexol levels achieved following use of the 3.4 g implant were superior to those achieved with the 1.7 g naltrexone implant, with naltrexone blood levels maintained above 2 ng/ml for a period of approximately 6.3 months compared to 3 months, respectively. The implications of this in managing the heroin-dependent patient, especially those who find it difficult to shift away from dependent use patterns, are discussed. (Review' s abstract) |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 16 |
Affiliation : |
Sch. Psychiat. Clin. Neurosc., Univ. Western Australia, 35 Stirling Highway, Crawley, WA 6009 Australie. Australia. |
Numéro Toxibase : | 207426 |
Centre Emetteur : | 02 Coordonnateur |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil